Tandospirone activates neuroendocrine and ERK (MAP kinase) signaling pathways specifically through 5-HT1A receptor mechanisms in vivo

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 371, Issue 1, 2005, Pages 18-26

  Sullivan, Nicole R ^a,b   Crane, James W ^a   Damjanoska, Katerina J ^a   Carrasco, Gonzalo A ^a   D'Souza, Deborah N ^a   Garcia, Francisca ^a   Van De Kar, Louis D ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Wyeth Ayerst Research   (United States)

Author keywords

5 HT1A receptor; ACTH; Corticosterone; Dorsal raph ; MAP kinase; Oxytocin; Paraventricular nucleus; Prolactin

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXYTOCIN; PROLACTIN; SEROTONIN 1A RECEPTOR; TANDOSPIRONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOSTERONE RELEASE; CORTICOTROPIN BLOOD LEVEL; DORSAL RAPHE NUCLEUS; DOSE TIME EFFECT RELATION; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; MALE; NEUROENDOCRINE SYSTEM; NONHUMAN; OXYTOCIN BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; IMMUNOBLOTTING; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROSECRETORY SYSTEMS; PIPERAZINES; PYRIDINES; PYRIMIDINES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION;

EID: 15044341121     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-1005-7     Document Type: Article

References (71)

1. Andrade R, Nicoll RA (1987) Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn-Schmiedebergs Arch Pharmacol 336:5-10
2. Andrade R, Malenka RC, Nicoll RA (1986) A G protein couples serotonin and GABAB receptors to the same channels in hippocampus. Science 234:1261-1265
3. Argyropoulos SV, Sandford JJ, Nutt DJ (2000) The psychobiology of anxiolytic drugs. II. Pharmacological treatments of anxiety. Pharmacol Ther 88:213-227
4. 1C receptors induce oxytocin release in the male rat. Brain Res 611:330-332
5. 2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses. Endocrinology 134:1127-1131
6. Ben-Jonathan N (1985) Dopamine: a prolactin inhibiting hormone. Endocr Rev 6:564-589
7. Blier P, Curet O, Chaput Y, de Montigny C (1991) Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine. II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission. Neuropharmacology 30:691-701
8. 1A receptors in the dorsal raphe and hippocampus. II. Effect of pertussis and cholera toxins. J Pharmacol Exp Ther 265:16-23
9. Carrasco GA, Van de Kar LD (2003) Neuroendocrine pharmacology of stress. Eur J Pharmacol 463:235-272
10. Chen J, Shen C, Meller E (2002) 5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain. Eur J Pharmacol 452:155
11. 1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. J Pharmacol Exp Ther 277:1259-1266
12. Cowen DS, Sowers RS, Manning DR (1996) Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine1A receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis. J Biol Chem 271:22297-22300
13. Cowen PJ (1998) Neuroendocrine challenge tests: what can we learn from them? In: Van de Kar LD (ed) Methods in neuroendocrinology. CRC, Boca Raton, pp 205-223
14. Crane JW, Shimizu KJ, Damjanoska KJ, Garcia F, Charumas V, Carrasco GA, Sullivan Hanley NR, D'Souza DN, Peterson B, Zhang Y, Van de Kar LD (2003) MAP kinase activation in the rat brain following systemic administration of a selective 5-HT1A receptor agonist [abstract]. Neurosci Abst 362.15
15. Eison MS (1989) The new generation of serotonergic anxiolytics: possible clinical roles. Psychopathology 22 [Suppl 1]:13-20
16. Feighner JP, Boyer WF (1989) Serotonin-1A anxiolytics: an overview. Psychopathology 22 [Suppl 1]:21-26
17. 1A receptors. Eur J Pharmacol 237:283-291
18. 1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther 278:752-762
19. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88
20. Fujino Y, Nakajima M, Tsuboi Y, Baba Y, Yamada T (2002) Clinical effectiveness of tandospirone citrate (5-HT1A agonist) on patients with progressive supranuclear palsy. Rinsho Shinkeigaku 42:42-44
21. 1A receptor via a G protein βgamma-subunit-initiated pathway. Biochemistry 35: 13716-13722
22. Godbout R, Chaput Y, Blier P, de Montigny C (1991) Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine. I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology 30:679-690
23. 1A receptors. Brain Res 770: 10-17
24. Gundlah C, Pecins-Thompson M, Schutzer WE, Bethea CL (1999) Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res Mol Brain Res 63:325-339
25. Hamik A, Oksenberg D, Fischette C, Peroutka SJ (1990) Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 28:99-109
26. Handley SL, McBlane JW (1993) 5HT drugs in animal models of anxiety. Psychopharmacology 112:13-20
27. Hanley NR, Van de Kar LD (2003) Serotonin and the neuroendocrine regulation of the hypothalamic-pituitary-adrenal axis in health and disease. Vitam Horm 66:189-255
28. Hensler JG (2003) Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 72: 1665-1682
29. Jones BJ, Blackburn TP (2002) The medical benefit of 5-HT research. Pharmacol Biochem Behav 71:555-568
30. Kenakin T (1988) Are receptors promiscuous? Intrinsic efficacy as a transduction phenomenon. Life Sci 43:1095-1101
31. 1A agonist 8-OH-DPAT in male rats. Brain Res 630:148-156
32. 1A receptors. J Pharmacol Exp Ther 282:1581-1590
33. 1A) in 5-HT transporter knock-out mice: gender and brain region differences. J Neurosci 20:7888-7895
34. Liposits Z, Phelix C, Paull WK (1987) Synaptic interaction of serotonergic axons and corticotropin releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. A light and electron microscopic immunocytochemical study. Histochemistry 86:541-549
35. Lowry CA (2002) Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. J Neuroendocrinol 14:911-923
36. Mannoury la Cour, Mestikawy SE, Rumajogee P, Bernard R, Miquel MC, Hamon M, Lanfumey L (2001) Regional differences in G proteins coupled to 5-HT1A receptors in the rat brain. Neurosci Abstr 380.7
37. Markstein R, Hoyer D, Engel G (1986) 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn-Schmiedebergs Arch Pharmacol 333:335-341
38. Martin KF, Mason R (1987) Isapirone is a partial agonist at 5-hydroxytryptamine 1A (5-HT1A) receptors in the rat hippocampus: electrophysiological evidence. Eur J Pharmacol 141: 479-483
39. Matheson GK, Knowles A, Gage D, Michel C, Guthrie D, Bauer C, Blackbourne J, Weinzapfel D (1997) Modification of hypothalamic-pituitary-adrenocortical activity by serotonergic agents in the rat. Pharmacology 55:59-65
40. 1A agonists. Mol Pharmacol 37:231-237
41. Meltzer HY, Simonovic M, Fang VS, Gudelsky GA (1982) Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover. Psychopharmacology 78:49-53
42. Meltzer HY, Fleming R, Robertson A (1983) The effect of buspirone on prolactin and growth hormone secretion in man. Arch Gen Psychiatry 40:1099-1102
43. Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ, Shemer A (1992) Kinetics, brain uptake, and receptor binding of tandospirone and its metabolites 1-(2-pyrimidinyl)-piperazine. J Clin Psychopharmacol 12:341-345
44. Miyata S, Hamamura T, Yoshinaga J, Nakamura Y, Imamura T, Hikiji A, Kuroda S (2001) Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to L-threo-3,4-dihydroxyphenylserine. Clin Neuropharmacol 24:232-234
45. iβgamma stimulates mitogen-activated protein kinase via NAD(P)H oxidase and reactive oxygen species upstream of src in Chinese hamster ovary fibroblasts. Biochem J 347:61-67
46. Mulroney SE, Skudlarek C, Shemer A, Lumpkin MD, Kellar KJ (1994) Tandospirone stimulates prolactin secretion in the rat by an action at serotonin-1A receptors. J Pharmacol Exp Ther 268:862-867
47. Nakayama T, Suhara T, Okubo Y, Ichimiya T, Yasuno F, Maeda J, Takano A, Saijo T, Suzuki K (2002) In vivo drug action of tandospirone at 5-HT(1A) receptor examined using positron emission tomography and neuroendocrine response. Psychopharmacology (Berl) 165:37-42
48. Ninan PT (1999) The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 60 [Suppl 22]:12-17
49. Penington NJ, Kelly JS (1993) Ionic dependence of a slow inward tail current in rat dorsal raphe neurones. J Physiol 464:33-48
50. + currents activated by 5-HT1A receptors on dorsal raphe neurones of the adult rat. J Physiol 469:387-405
51. Peroutka SJ (1985) Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry 20:971-979
52. 1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 127:1751-1764
53. Routledge C (1996) Development of 5-HT1A receptor antagonists. Behav Brain Res 73:153-156
54. 1A receptors in vivo. J Neurosci 20:3095-3103
55. Shimizu H, Hirose A, Tatsuno T, Nakamura M, Katsube J (1987) Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn J Pharmacol 45:493-500
56. 1 receptor. Eur J Pharmacol 157:173-181
57. 1B agonists. Synapse 1:3-9
58. 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 27:707-715
59. Steel RGD, Torrie JH (1960) Principles and procedures of statistics with special reference to the biological sciences. McGraw-Hill, New York
60. Van de Kar LD (1997) 5-HT receptors involved in the regulation of hormone secretion. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors. Springer, Berlin Heidelberg New York, pp 537-562
61. Van de Kar LD, Rittenhouse PA, Li Q, Levy AD, Brownfield MS (1995) Hypothalamic paraventricular, but not supraoptic neurons, mediate the serotonergic stimulation of oxytocin secretion. Brain Res Bull 36:45-50
62. Vanhoose AM, Emery M, Jimenez L, Winder DG (2002) ERK activation by G-protein-coupled receptors in mouse brain is receptor identity-specific. J Biol Chem 277:9049-9053
63. Watanabe H, Arahata Y, Tadokoro M, Kato T, Sobue G (2000) Effects of tandospirone citrate on frozen gait in patients with early stage of progressive supranuclear palsy, investigated by walk-induced activation single photon emission computed tomography method. Rinsho Shinkeigaku 40:1130-1132
64. 1A receptors in rat brain following antidepressant drug treatment. Synapse 4:347-352
65. 1A agonists measured with the forced swim test. Psychopharmaco logy 101:497-504
66. 2 receptor subtype mRNAs in rat brain. J Comp Neurol 351:357-373
67. Yamawaki S (1999) The use and development of anxiolytics in Japan. Eur Neuropsychopharmacol 9 [Suppl 6]:S413-S419
68. 1A receptors in the rat medial frontal cortex. Neurochem Int 40:355-360
69. Yu H, Lewander T (1997) Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur Neuropsychopharmacol 7:165-172
70. Zhang Y, Gray TS, D'Souza DN, Carrasco GA, Damjanoska KJ, Dudas B, Garcia F, Zainelli GM, Sullivan Hanley NR, Battaglia G, Muma NA, Van de Kar LD (2004) Desensitization of 5-HT1A receptors by 5-HT2A receptors in neuroendocrine neurons in vivo. J Pharmacol Exp Ther 310:59-66
71. Zubiaur M, Fernandez O, Ferrero E, Salmeron J, Malissen B, Malavasi F, Sancho J (2002) CD38 is associated with lipid rafts and upon receptor stimulation leads to Akt/protein kinase B and Erk activation in the absence of the CD3-zeta immune receptor tyrosine-based activation motifs. J Biol Chem 277:13-22